Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 4041 - 4048 of 12107 results
USPTO Releases Final Rules on PTA Calculations in view of Supernus
June 23, 2020| Blog| Viewpoint
Travel Ban Restricts Entry to the U.S. of Certain Foreign Nationals in the H, L and J Visa Categories
June 23, 2020| Alert| Viewpoint
Are Design Patents Missing From Your IP Portfolio?
June 23, 2020| Blog| Viewpoint
“Two-Tier” Arbitration: Progress in Enforcement of International Arbitral Awards in India
June 23, 2020| Blog| Viewpoint
Trump To Suspend New Work Visas Through 2020
June 23, 2020| News
IRS Issues Proposed Regulations on Section 1031 Like-Kind Exchanges
June 22, 2020| Alert| Viewpoint
NIST Provides Important Guidance For IOT Industry
June 22, 2020| Blog| Viewpoint
FINRA Revises Rule 4530 Problem Codes for Regulation Best Interest
June 22, 2020| Blog| Viewpoint
News & Press Releases
SEC’s Pharmaceutical Insider Trading Case Yields Quick Deals
August 19, 2025
Bloomberg Law featured a statement from Member Jason P.W. Halperin in its coverage of a pharmaceutical insider trading case brought by the SEC. Jason and the Mintz team of Sean Prosser and Elizabeth Platonova represented Robert Yedid in reaching a resolution in which the client pled guilty and, along with the other defendants, entered into consent orders with the SEC.
Mintz Advises Oppenheimer & Co. and Initial Purchasers in $475M Convertible Senior Notes Offering by WisdomTree
August 19, 2025
Mintz represented Oppenheimer & Co., as sole book-running manager, and Craig-Hallum Capital Group and Northland Securities, as co-managers, in the private placement of $475 million aggregate principal amount of 4.625% Convertible Senior Notes due 2030 issued by WisdomTree, Inc (NYSE: WT) (“WisdomTree”). The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|